<DOC>
	<DOCNO>NCT02627677</DOCNO>
	<brief_summary>The purpose study compare efficacy safety 2 start dos ponatinib compare nilotinib patient imatinib-resistant chronic myeloid leukemia ( CML ) chronic phase ( CP ) .</brief_summary>
	<brief_title>A Study Comparing Ponatinib Nilotinib Patients With Chronic Myeloid Leukemia</brief_title>
	<detailed_description>This multi-center , randomize study demonstrate efficacy safety 2 start dos ponatinib treatment CP-CML compare nilotinib . Eligible patient must chronic phase chronic myeloid leukemia ( CP-CML ) , resistant first-line imatinib treatment receive tyrosine kinase inhibitor ( TKIs ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Ponatinib</mesh_term>
	<criteria>1 . Have CPCML resistant firstline imatinib treatment . 2 . Be male female ≥18 year old . 3 . Have Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 4 . Have adequate renal function define follow criterion : • Serum creatinine ≤1.5 × upper limit normal ( ULN ) institution . 5 . Have adequate hepatic function define follow criterion : Total serum bilirubin ≤1.5 × ULN , unless due Gilbert 's syndrome Alanine aminotransferase ( ALT ) ≤2.5 × ULN ≤5 × ULN leukemic infiltration liver present Aspartate aminotransferase ( AST ) ≤2.5 × ULN ≤5 × ULN leukemic infiltration liver present . 6 . Have normal pancreatic status define follow criterion : Serum lipase amylase ≤1.5 × ULN . 1 . Have previously treat approve investigational TKIs imatinib treat imatinib within 14 day prior receive study drug . 2 . Have previously treat antiCML therapy hydroxyurea , include interferon , cytarabine , immunotherapy , cytotoxic chemotherapy , radiotherapy , investigational therapy . 3 . Underwent autologous allogeneic stem cell transplant . 4 . Are CCyR MMR . 5 . Have clinically significant , uncontrolled , active cardiovascular disease , specifically include , restrict : Any history myocardial infarction ( MI ) , unstable angina , cerebrovascular accident , transient ischemic attack ( TIA ) Any history peripheral vascular infarction , include visceral infarction Any history revascularization procedure , include vascular surgery placement stent History venous thromboembolism , include deep venous thrombosis , superficial venous thrombosis , pulmonary embolism , within 6 month prior enrollment Congestive heart failure ( New York Heart Association [ NYHA ] class III IV ) within 6 month prior enrollment leave ventricular ejection fraction ( LVEF ) less 45 % le institutional low limit normal ( whichever high ) within 6 month prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>CML</keyword>
	<keyword>CP-CML</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Leukemia , Myeloid</keyword>
	<keyword>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</keyword>
	<keyword>Neoplasms Histologic Type</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Myeloproliferative Disorders</keyword>
	<keyword>Bone Marrow Diseases</keyword>
	<keyword>Hematologic Diseases</keyword>
</DOC>